Citations

Showing 10 of 108119 citations.

Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
Benedict, Ágnes , Panjabi, Sumeet , Houisse, Ivan, Campioni, Marco, Giannopoulou, Andromachi, Aggarwal, Sanjay , Jakubowiak, Andrzej , Fonseca, Rafaël

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8021-8021

10.1200/jco.2016.34.15_suppl.8021 Get It

Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.
Richardson, Paul G. , Palumbo, Antonio , Viterbo, Luísa, Nagler, Arnon , Yehuda, Dina Ben , Pour, Luděk, Langer, Christian , Pluta, Andrzej, Berg, Deborah, Velde, Helgi van de , Esseltine, Dixie-Lee, Bacco, Alessandra Di , Richardson, Paul Gerard Guy , Avet‐Loiseau, Hervé , Ganly, Peter S. , Miguel, Jesús F. San , Rajkumar, S. Vincent , Bahlis, Nizar Jacques , Masszi, Tamás , Lin, Jianchang , Esseltine, Dixie‐Lee, Moreau, Philippe

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8018-8018

10.1200/jco.2016.34.15_suppl.8018 Get It

Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.
Kumar, Shaji , Lacy, Martha Q. , Zeldenrust, Steven R., Hayman, Suzanne R. , Kourelis, Taxiarchis , Lust, John A., Kapoor, Prashant , Kyle, Robert A. , Muchtar, Eli , Dispenzieri, Angela , Buadi, Francis K. , Leung, Nelson , Gonsalves, Wilson I. , Chakraborty, Rajshekhar , Dingli, David , Lin, Yi , Go, Ronald S. , Rajkumar, S. Vincent , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8016-8016

10.1200/jco.2016.34.15_suppl.8016 Get It

Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.
Timm, Michael, Morice, William G. , Lacy, Martha Q. , Kapoor, Prashant , Hayman, Suzanne R. , Lust, John A., Zeldenrust, Steven R., Kourelis, Taxiarchis , Hwa, Yi L. , Kyle, Robert A. , Kumar, Shaji , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Morice, William George , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Go, Ronald S. , Leung, Nelson , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8015-8015

10.1200/jco.2016.34.15_suppl.8015 Get It

Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Chanan‐Khan, Asher , Agarwal, Amit , Kumar, Shaji , Diehl, Susan, Cordero, Jaclyn, Munasinghe, Wijith, Zhu, Ming , Maciag, Paulo , Verdugo, Maria E., Moreau, Philippe , Roberts, Andrew W. , Facon, Thierry T.F. , Touzeau, Cyrille , Ross, Jeremy A. , Salem, Ahmed Hamed , Leverson, Joel D. , Harrison, Simon J

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8011-8011

10.1200/jco.2016.34.15_suppl.8011 Get It

A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results.
Krishnan, Amrita , Kapoor, Prashant , Kumar, Shaji , Htut, Myo , Karanes, Chatchada , Rosenzweig, Michael , Sahebi, Firoozeh , Somlo, George, Duarte, Lupe, Forman, Stephen J. , Palmer, Joycelynne Michelle , Lonial, Sagar , Nathwani, Nitya , Berdeja, Jesús G.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8008-8008

10.1200/jco.2016.34.15_suppl.8008 Get It

Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
Martin, Thomas G. , Vij, Ravi , Cole, Craig E. , Atanackovic, Djordje , Zonder, Jeffrey A. , Bensinger, William, Zimmerman, Todd M., Lendvai, Nikoletta , Gasparetto, Cristina , Kumar, Shaji , Oprea, Corina, Richter, Joshua , Kaufman, Jonathan L. , Mıkhael, Joseph , Dimopoulos, Meletios Α. , Hari, Parameswaran , Ocio, Enrique M. , Charpentier, Éric , Strickland, Stephen Anthony , Miguel, Jesús F. San

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8005-8005

10.1200/jco.2016.34.15_suppl.8005 Get It

Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).
Abeykoon, Jithma P. , Kumar, Shaji , King, Rebecca L. , Kyle, Robert A. , Hayman, Suzanne R. , Lacy, Martha Q. , Thompson, Carrie A. , Lust, John A., Ansell, Stephen M. , Kapoor, Prashant , Paludo, Jonas , Gertz, Morie A. , Buadi, Francis K. , Habermann, Thomas M. , Dingli, David , Witzig, Thomas E. , Dispenzieri, Angela , Go, Ronald S. , Gonsalves, Wilson I. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7552-7552

10.1200/jco.2016.34.15_suppl.7552 Get It

Beyond maximum grade: A novel method to assess toxicity over time in clinical trials of targeted therapy in lymphoma.
Thanarajasingam, Gita , Atherton, Pamela J. , Pederson, Levi , Novotny, Paul J. , Sloan, Jeff A. , Grothey, Axel, Kumar, Shaji , Habermann, Thomas M. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7546-7546

10.1200/jco.2016.34.15_suppl.7546 Get It